With the implementation of the EU GMP Annex 1 ("Manufacture of Sterile Medicinal Products"), pharmaceutical companies are facing new challenges, particularly in the fill-and-finish processes—the filling and final processing of medicinal products. Annex 1 introduces expanded requirements for the op…

The implementation of EU GMP Annex 1, which sets strict requirements for the production of sterile medicines, presents new challenges for pharmaceutical companies. In the foreseeable future, Ralf Wagner, Sales Director for the DACH region, Portugal and Spain at Optima Pharma, believes that glove int…

With the implementation of the EU GMP Annex 1 ("Manufacture of Sterile Medicinal Products"), pharmaceutical companies are facing new challenges, particularly in the fill-and-finish processes—the filling and final processing of medicinal products. Annex 1 introduces expanded requirements for both e…

The Optima group has completed the generational change in its management: The group with around 3,150 employees at more than 20 locations in Germany and abroad, will be led by Stefan König, Hans Bühler, Marco Beyl and Johannes-Thomas Grobe.

Building a stable management team for the coming years: This w…

The Optima Group has received the highest recognition for its sustainability efforts. This reflects Optima's commitment in the areas of the environment, labor and human rights, ethics, and sustainable sourcing.

Optima was awarded the Platin Medal by the sustainability assessment platform  EcoVadis…

From June 10-14, 2024 Optima will be at ACHEMA in Frankfurt am Main. At the world's leading trade show for the process industry, the packaging and filling equipment provider will present its complete, integrated turnkey solutions for the pharmaceutical and biotech industries. Visitors at the booth A…